Literature DB >> 3546716

Treatment of intestinal E. histolytica and G. lamblia with metronidazole, tinidazole and ornidazole: a comparative study.

S Bassily, Z Farid, N A el-Masry, E M Mikhail.   

Abstract

Metronidazole, tinidazole and ornidazole were compared in patients treated for Entamoeba histolytica or Giardia lamblia intestinal infections. Only patients with three positive stool specimens for trophozoites and/or cysts of E. histolytica or G. lamblia by the merthiolate iodine formaldehyde (MIFC) technique were included. Criteria for cure were at least 10 negative stool specimens over 3 weeks after completing therapy. Fifty-three male patients (aged 9-65 years) had E. histolytica infection. Seventeen received metronidazole (1.5 g daily for 10 days), 18 tinidazole (1.5 g daily for 10 days) and 18 ornidazole (1 g daily for 10 days). Metronidazole yielded 88%, tinidazole 67% and ornidazole 94% cure rates. Side reactions were minor. Eighty patients had G. lamblia infection, of whom 20 received metronidazole (0.5 g daily for 10 days), 30 tinidazole (single 2 g dose) and 30 ornidazole (single 1 g dose). Cure rates were 95% for metronidazole, 90% for tinidazole and 97% for ornidazole with no side reactions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3546716

Source DB:  PubMed          Journal:  J Trop Med Hyg        ISSN: 0022-5304


  15 in total

1.  Efficacy and safety of morinidazole in pelvic inflammatory disease: results of a multicenter, double-blind, randomized trial.

Authors:  C Cao; A Luo; P Wu; D Weng; H Zheng; S Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-03-06       Impact factor: 3.267

2.  Amebiasis in the newborn.

Authors:  Ayla Güven
Journal:  Indian J Pediatr       Date:  2003-05       Impact factor: 1.967

Review 3.  Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by "amitochondriate" protozoan parasites.

Authors:  Vahab Ali; Tomoyoshi Nozaki
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

4.  A rapid, high-throughput viability assay for Blastocystis spp. reveals metronidazole resistance and extensive subtype-dependent variations in drug susceptibilities.

Authors:  Haris Mirza; Joshua D W Teo; Jacqui Upcroft; Kevin S W Tan
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

Review 5.  WITHDRAWN: Drugs for treating giardiasis.

Authors:  J O M Zaat; T H G Mank; W J J Assendelft
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

Review 6.  Small Intestinal Infections.

Authors:  Khushboo Munot; Donald P Kotler
Journal:  Curr Gastroenterol Rep       Date:  2016-06

Review 7.  Drugs for treating giardiasis.

Authors:  Carlos E Granados; Ludovic Reveiz; Luis G Uribe; Claudia P Criollo
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

8.  Phenotypic and genotypic variation in Giardia lamblia isolates during chronic infection.

Authors:  P D Butcher; A M Cevallos; S Carnaby; E M Alstead; E T Swarbrick; M J Farthing
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

9.  Single-dose ornidazole versus seven-day metronidazole therapy of giardiasis in Kibbutzim children in Israel.

Authors:  B Oren; E Schgurensky; M Ephros; I Tamir; R Raz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

10.  The old and new therapeutic approaches to the treatment of giardiasis: where are we?

Authors:  Haendel G N O Busatti; Joseph F G Santos; Maria A Gomes
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.